Skip to main
OPCH

OPCH Stock Forecast & Price Target

OPCH Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 55%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Option Care Health is facing some headwinds in the autoimmune and chronic inflammatory therapy segment, but management is taking steps to improve leverage and optimize procurement activities. The company's capital allocation priorities prioritize internal investment and M&A, which aligns with previous management commentary. Although there are some concerns about the first quarter earnings report and guidance, Option Care is well-positioned in the home and alternate-site infusion market and has historically exceeded financial guidance. The company's improved margins and momentum in acute therapies are also positive indicators.

Bears say

Option Care Health is facing headwinds in its chronic therapies revenue, as well as a negative cash flow from operations, leading to substantial capital expenditures. They have a history of overpromising and underdelivering, leading to negative reactions from shareholders. Additionally, the portfolio is de-risked, but it remains uncertain if the company can resume its previous track record of margin expansion. This, combined with the negative cash flow and reliance on a single drug, makes Option Care Health's stock risky for investors.

OPCH has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 55% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Option Care Health (OPCH) Forecast

Analysts have given OPCH a Buy based on their latest research and market trends.

According to 11 analysts, OPCH has a Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Option Care Health (OPCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.